Phreesia reports today with the stock at $9.13 — a level that two of the most recently active analysts now consider fair value, and well below where the rest of the Street still sits.
The analyst picture heading into this print is one of accelerating capitulation. Wells Fargo and Barclays both downgraded PHR to Equal-Weight within the past two weeks, with targets of $9 and $10 respectively — effectively removing any upside case at current prices. Those moves follow a broader wave on March 31, when JPMorgan, Citi, and Truist all stepped down from positive ratings and slashed targets from the $24–$33 range into the low teens. The consensus mean target of $15.06 now overstates where the most recent movers have landed, and the remaining bulls — Canaccord at $22 and Stephens at $20 — look increasingly isolated. The bear case is straightforward: a $37 million FY27 revenue guidance cut, Network Solutions commitments drying up, and subscription growth decelerating to low single digits from prior double-digit guidance. Bulls counter that Q4 revenue of $127.1 million grew 15.9% year-over-year, that the AccessOne acquisition diversifies PHR away from pharma advertising, and that AI-driven efficiency gains could rebuild margins over time. Neither camp has much help from EPS momentum, which ranks in the bottom quartile of the universe on both 30- and 90-day windows.
Short interest and borrow conditions tell a notably different story from the analyst exodus. SI has drifted up roughly 7.7% over the past month to 6.4% of the free float — elevated but not extreme, and rising gradually rather than aggressively. Cost to borrow is 0.45%, low by any standard. Availability is exceptionally loose at over 4,600% of short interest, meaning there is no scarcity of shares to borrow for anyone who wants to press the short. The ORTEX short score of 42 sits in a moderate range, consistent with the recent peer note observation that the stock's underperformance reflects fundamental concerns rather than a crowded-short dynamic. Options positioning reinforces the same read: the put/call ratio at 0.25 is actually below its 20-day average of 0.28 — options traders are not rushing for downside protection.
The last confirmed earnings reaction on record — the March print — saw the stock fall nearly 24% in a single session, recovering to a 17% five-day loss. That reset, combined with the subsequent analyst downgrades, has already priced in a great deal of the bad news. The earnings report will test whether the revised guidance floor is credible, or whether Network Solutions weakness and subscription headwinds run deeper than management's updated numbers suggest.
See the live data behind this article on ORTEX.
Open PHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
